QCM-D surpassing clinical standard for the dose administration of new oral anticoagulant in the patient of coagulation disorders

Munawar Hussain; Hans Peter Wendel; Katrin Schmidt; Elisabeth Langer; Mareike Kristina Körber; Oksana Faul; Hinnak Northoff; Christian von Heymann; Frank K Gehring

doi:10.1016/j.bios.2017.12.043

QCM-D surpassing clinical standard for the dose administration of new oral anticoagulant in the patient of coagulation disorders

Biosens Bioelectron. 2018 May 1:104:15-20. doi: 10.1016/j.bios.2017.12.043. Epub 2017 Dec 27.

Authors

Munawar Hussain¹, Hans Peter Wendel², Katrin Schmidt³, Elisabeth Langer⁴, Mareike Kristina Körber³, Oksana Faul⁵, Hinnak Northoff⁵, Christian von Heymann⁶, Frank K Gehring⁵

Affiliations

¹ Biosensor Research Group, Thoracic, Cardiac and Vascular Surgery Department, Tuebingen University, Germany. Electronic address: munawar_arif@hotmail.com.
² Biosensor Research Group, Thoracic, Cardiac and Vascular Surgery Department, Tuebingen University, Germany.
³ Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institut of Health, Germany; Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Campus Virchow Klinkum, Augustenburger Platz 1, 13353 Berlin, Germany.
⁴ Labor Berlin-Charite Vivantes, GmbH, Berlin, Germany; Institute for Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité-Universitätsmedizin Berlin, Campus Charité Virchow Klinikum, Berlin, Germany.
⁵ Institute of Clinical and Experimental Transfusion Medicine, Tuebingen University, Germany.
⁶ Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institut of Health, Germany; Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Campus Virchow Klinkum, Augustenburger Platz 1, 13353 Berlin, Germany; Vivantes Klinikum im Friedrichshain, Department of Anesthesiology, Intensive Care Medicine, Emergency Medicine and Pain Medicine, Landsberger Allee 49, 10249 Berlin, Germany.

PMID: 29294406
DOI: 10.1016/j.bios.2017.12.043

Abstract

The study focuses the dose administration of dabigatran to avoid the deaths due to hemorrhagic complications and thromboembolic stroke in clinics worldwide. To target the issue, a novel emerging acoustic technology, namely ''Quartz Crystal Microbalance with Dissipation'' (QCM-D) has been applied, while the acoustic assays namely ''activated Partial Thromboplastin Time'' (aPTT) and ''Prothrombinase complex-induced Clotting Test'' (PiCT) have been compared with the standard methods in parallel. Both techniques have been applied to 300 samples, including 220 plasma samples of patients suffering coagulation disorders and 80 plasma samples of non-patients. In comparison, the coagulation times of the acoustic aPTT and PiCT yielded an excellent correlation with the standard methods with in analytical standard deviation limits. Finally, the acoustic aPTT assay is the ''gold standard'' for a dose administration of the new oral anticoagulant, where the Δf/ΔΓ ratio of the acoustic assay demonstrates that dabigatran with FEIBA 50 combination could be a safe remedy to avoid the deaths in clinics.

Keywords: Coagulation disorders; Dabigatran; Patient plasma; PiCT; QCM-D; aPTT.

MeSH terms

Biosensing Techniques*
Blood Coagulation / drug effects
Blood Coagulation Disorders / blood*
Blood Coagulation Disorders / pathology
Blood Coagulation Tests
Dabigatran / administration & dosage
Factor V / isolation & purification
Factor Xa / isolation & purification
Female
Humans
Male
Partial Thromboplastin Time
Quartz Crystal Microbalance Techniques*
Thrombin / isolation & purification*

Substances

prothrombinase complex
Factor V
Thrombin
Factor Xa
Dabigatran